Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seven analysts rate Avalyn Pharma a consensus “Moderate Buy,” with three buys, two strong buys, one hold and one sell. The average 12-month price target is $60, well above the reported $26.04 opening price.
• Avalyn reported a quarterly loss of $0.98 per share, beating the consensus estimate of a $1.03 loss; analysts expect a full-year loss of approximately $3.86 per share.
• Several institutional investors recently initiated positions, including Montanova Capital, State Street and Braidwell. Avalyn is a clinical-stage biotechnology company developing inhaled therapies, led by its AP01 candidate for pulmonary fibrosis.

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $60.00.

A number of brokerages recently commented on AVLN. Weiss Ratings began coverage on Avalyn Pharma in a research report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Morgan Stanley upped their price target on Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Thursday, August 13th. Raymond James Financial initiated coverage on Avalyn Pharma in a report on Friday, October 2nd. They issued an "outperform" rating and a $60.00 price target on the stock. Finally, Wall Street Zen cut Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th.

Avalyn Pharma Stock Performance

AVLN opened at $26.04 on Monday. Avalyn Pharma has a 1-year low of $22.24 and a 1-year high of $40.17. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.15 billion and a P/E ratio of -1.14. The firm has a fifty day moving average of $31.37.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, research analysts forecast that Avalyn Pharma will post -3.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Avalyn Pharma

A number of large investors have recently modified their holdings of the company. Manchester Capital Management LLC acquired a new position in Avalyn Pharma during the third quarter worth $36,000. Bank of New York Mellon Corp bought a new position in Avalyn Pharma in the 2nd quarter valued at about $1,321,000. State Street Corp bought a new position in shares of Avalyn Pharma in the second quarter valued at approximately $10,501,000. Braidwell LP purchased a new position in shares of Avalyn Pharma during the second quarter valued at approximately $26,382,000. Finally, Montanova Capital LLC bought a new stake in Avalyn Pharma during the second quarter worth $82,402,000.

About Avalyn Pharma

Avalyn Pharma, Inc NASDAQ: AVLN is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company's research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.